NIOX MINO(R) Set to Dramatically Improve Airway Inflammatory Disease
Management through Personalized Inflammation Control
NEW PROVIDENCE, N.J., March 4 /PRNewswire/ -- Aerocrine, Inc. (http://www.aerocrine.com) today announced that NIOX MINO (http://www.nioxmino.com), a hand- held point-of-care device for the measurement of airway inflammation, has been 510(k) cleared by the U.S. Food and Drug Administration (FDA). Physicians in the U.S. now have a highly accurate, non-invasive and convenient technology that is appropriate for use in a doctor's office, ultimately helping them improve how they treat asthma patients.
NIOX MINO provides accurate, reproducible and immediate measurement of fractional exhaled nitric oxide (FENO), a validated method for assessing asthma-related airway inflammation. NIOX MINO is the first hand-held device to measure airway inflammation -- an underlying cause of inflammatory airway diseases -- helping physicians improve patient outcomes and reduce healthcare expenditures.
"NIOX MINO answers the need for a user friendly, non-invasive, accurate, and cost effective tool that enables any physician to monitor the underlying process of asthma-airway inflammation," said Peter B. Boggs, M.D., Clinical Professor of Pediatrics and Medicine, LSU School of Medicine, Shreveport." What is important about this is that the control of airway inflammation is the key to the successful management of asthma, and this tool makes this possible."
Millions of people living with asthma, including many children, are not
receiving optimal treatment. All patients are different, requiring
different treatments and dosages. Therefore, airway inflammatory disease
|SOURCE Aerocrine, Inc.|
Copyright©2008 PR Newswire.
All rights reserved